GEP44 / SureNano Science - LARVOL DELTA

SureNano Science Ltd. Acquires GlucaPharm Inc., Advancing Second-Generation FDA Pathway GLP-1 Drug Development (Newsfile) - "GlucaPharm's GEP44 developments directly align with SureNano's strategy of next-generation solutions that improve performance, tolerability, and delivery, mirroring SureNano's core value proposition: to improve how advanced therapeutics are delivered and experienced by patients....GlucaPharm is advancing GEP44 in collaboration with an experienced Australian contract research organization (CRO), with an IND-enabling FDA study followed by Phase I Clinical Trial expected to commence in Australia in the coming months. Key development milestones are anticipated over the next six to nine months, including IND progression and early clinical validation."

M&A • New P1 trial • Obesity